Protective effects of resveratrol against 5-fluorouracil-induced oxidative stress and inflammatory responses in human keratinocytes. 2021

Shu Chen, and Naofumi Tamaki, and Yasusei Kudo, and Takaaki Tsunematsu, and Kaname Miki, and Naozumi Ishimaru, and Hiro-O Ito
Department of Preventive Dentistry, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan.

Although 5-fluorouracil (5-FU) is currently used as an anti-cancer chemotherapy, adverse effects such as oral mucositis potentially limit its clinical application. Additionally, the prevention of 5-FU-induced side effects are scarce. Resveratrol is known to decrease oxidative damage and inflammation. In this study, we examined the protective effects of resveratrol on 5-FU-induced oxidative stress and inflammatory responses in normal human keratinocytes (HaCaT cell) as in vitro oral mucositis model. HaCaT cells were exposed to 5-FU and simultaneously treated with resveratrol. The effects of resveratrol on 5-FU-induced cytotoxicity were evaluated using cell viability assay. The production of reactive oxygen species (ROS) was measured using a fluorescence spectrophotometer. The effects of resveratrol on nuclear factor erythroid 2-related factor 2 (Nrf2), silent information regulator transcript-1 (SIRT-1), and nuclear factor kappa B (NF-κB) signaling and inflammatory cytokine expression were examined. Resveratrol suppressed 5-FU-induced overproduction of ROS by upregulating anti-oxidant defense genes through Nrf2 activation and SIRT-1 expression. Concerning inflammatory responses, resveratrol suppressed the 5-FU-induced expression of pro-inflammatory cytokines via NF-κB nuclear translocation. Conversely, N-acetylcysteine reduced ROS levels without affecting the expression of pro-inflammatory cytokines. Resveratrol might be useful for preventing 5-FU-induced adverse effects by activating anti-oxidant and anti-inflammatory responses.

UI MeSH Term Description Entries

Related Publications

Shu Chen, and Naofumi Tamaki, and Yasusei Kudo, and Takaaki Tsunematsu, and Kaname Miki, and Naozumi Ishimaru, and Hiro-O Ito
January 2021, Antioxidants (Basel, Switzerland),
Shu Chen, and Naofumi Tamaki, and Yasusei Kudo, and Takaaki Tsunematsu, and Kaname Miki, and Naozumi Ishimaru, and Hiro-O Ito
October 2019, Antioxidants (Basel, Switzerland),
Shu Chen, and Naofumi Tamaki, and Yasusei Kudo, and Takaaki Tsunematsu, and Kaname Miki, and Naozumi Ishimaru, and Hiro-O Ito
May 2020, International journal of molecular sciences,
Shu Chen, and Naofumi Tamaki, and Yasusei Kudo, and Takaaki Tsunematsu, and Kaname Miki, and Naozumi Ishimaru, and Hiro-O Ito
January 2005, Photochemistry and photobiology,
Shu Chen, and Naofumi Tamaki, and Yasusei Kudo, and Takaaki Tsunematsu, and Kaname Miki, and Naozumi Ishimaru, and Hiro-O Ito
May 2023, Applied biochemistry and biotechnology,
Shu Chen, and Naofumi Tamaki, and Yasusei Kudo, and Takaaki Tsunematsu, and Kaname Miki, and Naozumi Ishimaru, and Hiro-O Ito
July 2022, Journal of personalized medicine,
Shu Chen, and Naofumi Tamaki, and Yasusei Kudo, and Takaaki Tsunematsu, and Kaname Miki, and Naozumi Ishimaru, and Hiro-O Ito
September 2008, Ecotoxicology and environmental safety,
Shu Chen, and Naofumi Tamaki, and Yasusei Kudo, and Takaaki Tsunematsu, and Kaname Miki, and Naozumi Ishimaru, and Hiro-O Ito
December 2009, Brain injury,
Shu Chen, and Naofumi Tamaki, and Yasusei Kudo, and Takaaki Tsunematsu, and Kaname Miki, and Naozumi Ishimaru, and Hiro-O Ito
January 2014, Iranian journal of pharmaceutical research : IJPR,
Shu Chen, and Naofumi Tamaki, and Yasusei Kudo, and Takaaki Tsunematsu, and Kaname Miki, and Naozumi Ishimaru, and Hiro-O Ito
August 2005, The Journal of surgical research,
Copied contents to your clipboard!